News for Benitec Biopharma Inc. (BNTC)

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Transaction Overview On December 31, 2024, Janus Henderson Group PLC executed a strategic transaction involving Benitec Biopharma Inc. The firm reduced its hold

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking

**media[540808]**

On December 31, 2024, Franklin Resources Inc., a prominent investment management firm, made a strategic move by acquiring 3,697,047 shares of Benitec Biopharma

HAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focused

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small size. Learn more on BNTC stock here.

Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Benitec Biopharma stock soars to 52-week high of $13.29

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

On November 29, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio), a prominent investment management firm, expanded its holdings in Benitec Biopharma Inc by a

HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focused

Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.

Enthusiasm about artificial intelligence helped drive collective gains in global equities during the second quarter of 2024. Click here to read the full fund letter.

In this piece, we will take a look at the 11 best ASX stocks to buy now.

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It is anticipated to generate an...